OptiBiotix Health signs agreement to distribute in Russia and Kazakhstan
has entered into a three-year distribution agreement with SilvEXPO, to distribute and commercialise its CholBiome® products in Russia and Kazakhstan.
It grants SilvExpo non-exclusive distribution rights for OptiBiotix’s CholBiome® products, which contain the cholesterol and blood pressure reducing LPLDL® strain.
The Russian probiotics market alone is estimated at €340 million with a 10% annual growth, according to Euromonitor. SilvExpo experience in these markets is set to enable OptiBiotix to introduce the CholBiome® range of products into the chain of pharmacies in one of the largest Eastern European markets for probiotics.
Per Rehné, Commercial Director of OptiBiotix, commented: "We are pleased to announce this agreement which extends the sales channel of our CholBiome® products into Russia and Kazakhstan where cardiovascular disease are the leading cause of morbidity and mortality.”
“We chose SilvExpo for its knowledge and speed to market and they have shown the ability to grow product sales in challenging markets.”
The company said that it anticipates that the agreement “could produce revenues quickly”.
Follow News & Updates from OptiBiotix here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.